Doylestown, Pennsylvania -- Atrin Pharmaceuticals has received $1.5 million in new venture equity and debt investment, according to an SEC regulatory filing.
Atrin is developing technology that was licensed from the University of Pennsylvania to create water-soluble, orally bioavailable, small molecule inhibitors of ATR.
Investors in the financing were not disclosed, nor was how the company intends to use the funding proceeds.
A total of nine investors participated in the offering.
Atrin is still seeking $500,000 in additional financing, according to the filing.
Minimum investment size per investor was listed as $25,000.